Surgery on Extracorporeal Circulation in Early and Advanced Non-Small Cell Lung Cancer

被引:18
|
作者
Kauffmann, Matthias [1 ]
Krueger, Tobias [1 ]
Aebert, Hermann [1 ]
机构
[1] Univ Tubingen Hosp, Dept Thorac Cardiac & Vasc Surg, Tubingen, Germany
关键词
lung cancer; NSCLC; cardiopulmonary surgery; extracorporeal circulation; cardiopulmonary bypass ECC; SINGLE-CENTER; RESECTION; SURVIVAL; BYPASS;
D O I
10.1055/s-0032-1331041
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Locally advanced (T4) non-small cell lung cancer (NSCLC) is principally amenable to surgery. For radical resection of cardiovascular structures, extracorporeal circulation (ECC) may be required. Tumor dissemination is a concern in this situation. In this study, we evaluate the long-term results of T4 NSCLC surgery with ECC and compare them with combined cardiopulmonary surgery for early-stage NSCLC and heart disease. Methods We retrospectively analyzed 16 patients undergoing surgery on ECC over a 13-year period. Eight patients suffered from T4 NSCLC (group A), and another eight patients suffered from coincidental T1-T2 NSCLC and heart disease (group B). Results In group A, five patients received neoadjuvant radiochemotherapy. Complete resection was achieved in all patients. Thirty-day mortality was one patient (12.5%) in each group. Six patients died from recurrent cancer with a median survival of 13.6 months in group A. Prognosis in patients with direct tumor invasion of the aortopulmonary window was a lot worse compared to those with atrial infiltration. One T4 patient who had only received surgery survived for 155 months without relapse. In group B, no NSCLC relapse occurred, and median survival was 21.6 months. All but one death in group B occurred due to cardiovascular incidents. Conclusions Surgery on ECC for T4 NSCLC gives satisfactory results. The site of infiltration appears to be most important for local tumor relapse. Long-term survival is possible in some cases. Simultaneous cardiac and pulmonary surgery resulted in good early and midterm outcomes without surgery-induced tumor propagation.
引用
收藏
页码:103 / 108
页数:6
相关论文
共 50 条
  • [31] Treatment of advanced non-small cell lung cancer in the elderly
    Sacco, Paola C.
    Maione, Paolo
    Palazzolo, Giovanni
    Gridelli, Cesare
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2018, 12 (09) : 783 - 792
  • [32] Surgical management of advanced non-small cell lung cancer
    Varela, Gonzalo
    Thomas, Pascal Alexandre
    JOURNAL OF THORACIC DISEASE, 2014, 6 : S217 - S223
  • [33] Optimized local therapy for locally advanced non-small cell lung cancer
    Billiet, Charlotte
    De Ruysscher, Dirk
    JOURNAL OF THORACIC DISEASE, 2017, 9 (07) : 1783 - 1785
  • [34] The use of immunotherapy in older patients with advanced non-small cell lung cancer
    Tagliamento, Marco
    Frelaut, Maxime
    Baldini, Capucine
    Naigeon, Marie
    Nencioni, Alessio
    Chaput, Nathalie
    Besse, Benjamin
    CANCER TREATMENT REVIEWS, 2022, 106
  • [35] Emerging Role of Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer
    Mulherkar, Ria
    Grewal, Amardeep S.
    Berman, Abigail T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (04) : 212 - 217
  • [36] Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer
    Kumar, Mukesh
    Ernani, Vinicius
    Owonikoko, Taofeek K.
    MOLECULAR ASPECTS OF MEDICINE, 2015, 45 : 55 - 66
  • [37] Radioimmunotherapy: a game-changer for advanced non-small cell lung cancer
    Xue, Huichan
    Chen, Yunshang
    Zhou, Yun
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [38] Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer
    Higgins, Jordyn P.
    Carlisle, Jennifer W.
    Moniri, Nader H.
    Gupta, Shruti
    Oduah, Eziafa I.
    Leal, Ticiana
    FUTURE ONCOLOGY, 2025, 21 (01) : 63 - 71
  • [39] The lymphadenectomy in non-small cell lung cancer
    Chiappetta, Marco
    VIDEO-ASSISTED THORACIC SURGERY, 2022, 7
  • [40] Paclitaxel for non-small cell lung cancer
    Ramalingam, S
    Belani, CP
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (08) : 1771 - 1780